Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$49.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

BioMarin Pharmaceutical Inc reaffirms FY 2014 revenue guidance - Conference Call


Wednesday, 14 May 2014 07:20pm EDT 

BioMarin Pharmaceutical Inc:Expects FY 2014 revenues to be in the $650 million to $680 million range.FY 2014 revenue of $675 million - Thomson Reuters I/B/E/S. 

Company Quote

132.31
-2.53 -1.88%
29 Jun 2015